Vanda Pharmaceuticals (VNDA) Tops Q3 EPS by 16c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. SBUX
9. AXP
10. ZETA

Go back to Vanda Pharmaceuticals (VNDA) Tops Q3 EPS by 16c

Vanda Pharmaceuticals Reports Third Quarter 2018 Financial Results

November 7, 2018 4:01 PM EST

WASHINGTON, Nov. 7, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2018.

Key Highlights:

Vanda reiterates 2018 net product sales guidance of $180 million to $200 million. Total net product sales from HETLIOZ® and Fanapt® were $49.1 million during the third quarter of 2018, a 4% increase compared to $47.4 million in the second quarter of 2018 and a 19% increase compared to $41.3 million in the third quarter of 2017.

HETLIOZ® (tasimelteon)

HETLIOZ® net product sales were $29.9 million in... More